We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acasti Pharma Inc | NASDAQ:ACST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.76 | 2.58 | 3.21 | 2.86 | 2.73 | 2.75 | 4,308 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
Acasti Pharma Inc. (the “Company”) held its Annual Meeting of Shareholders on October 10, 2023 (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and there was no solicitation in opposition to the Company’s board of director’s solicitation. Holders of a total of 4,078,661 of the Company’s common shares were present or represented by proxy at the Annual Meeting, representing 54.76% of the Company’s 7,448,033 common shares that were outstanding and entitled to vote at the Annual Meeting as of the record date of August 18, 2023. Set forth below are the matters acted upon by the Company’s shareholders at the Annual Meeting and the final voting results on each matter. Each of the proposals is described in further detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on August 25, 2023 (the “Proxy Statement”).
Proposal No. 1 – Election of Directors
The following nominees were elected as directors by the votes indicated to serve until the Company’s next annual meeting of shareholders, as set forth in the Proxy Statement:
Nominee |
Votes For |
% Votes For |
Withheld |
% Votes Withheld |
Non-Vote |
Vimal Kavuru |
2,746,424 |
97.82% |
61,122 |
2.18% |
1,271,115 |
A. Brian Davis |
2,761,502 |
98.36% |
46,044 |
1.64% |
1,271,115 |
S. George Kottayil |
2,758,885 |
98.27% |
48,662 |
1.73% |
1,271,115 |
Prashant Kohli |
2,758,939 |
98.27% |
48,607 |
1.73% |
1,271,115 |
Edward Neugeboren |
2,759,075 |
98.27% |
48,471 |
1.73% |
1,271,115 |
Proposal No. 2 – Appointment of Ernst & Young LLP
The proposal to appoint Ernst & Young LLP as the Company’s independent registered public accounting firm until the close of the Company’s next annual meeting shareholders and to authorize the Company’s board of directors to fix their remuneration was approved by the shareholders by the following vote:
For |
% For |
Against |
% Against |
Abstain |
% Abstain |
Non-Vote |
3,982,999 |
97.65% |
81,017 |
1.99% |
14,644 |
0.36% |
1 |
Proposal No. 3 – Advisory Vote to Approve Named Executive Officer Compensation
The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement was approved by the shareholders by the following vote:
For |
% For |
Against |
% Against |
Abstain |
% Abstain |
Non-Vote |
2,730,102 |
97.24% |
68,055 |
2.42% |
9,389 |
0.33% |
1,271,115 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ACASTI PHARMA INC. |
|
|
|
|
Date: |
October 11, 2023 |
By: |
/s/ Prashant Kohli |
|
|
|
Prashant Kohli |
Document And Entity Information |
Oct. 10, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Oct. 10, 2023 |
Entity Registrant Name | ACASTI PHARMA INC. |
Entity Central Index Key | 0001444192 |
Entity Emerging Growth Company | false |
Securities Act File Number | 001-35776 |
Entity Incorporation, State or Country Code | A8 |
Entity Tax Identification Number | 98-1359336 |
Entity Address, Address Line One | 2572 boul. Daniel-Johnson |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | Laval |
Entity Address, State or Province | QC |
Entity Address, Postal Zip Code | H7T 2R3 |
City Area Code | 450 |
Local Phone Number | 686-4555 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Shares, no par value per share |
Trading Symbol | ACST |
Security Exchange Name | NASDAQ |
1 Year Acasti Pharma Chart |
1 Month Acasti Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions